Inclusion Criteria:

          1. Male or non-pregnant, non-lactating female patients who are 18 years of age or older.

          2. CML-CP patients with positive Ph chromosome or BCR-ABL fusion genes.

          3. After any targeted BCR-ABL1 tyrosine kinase inhibitors (TKI) treatment, CML-CP
             patients with T315I mutation.

          4. Ability to understand and willingness to sign a written informed consent form. The
             consent form must be signed by the patient prior to any study-specific procedures.

          5. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2.

          6. Predicted life expectancy of ≥3 months.

          7. Organ function as indicated by the following laboratory indicators must be
             met（Hematological indicators require that no blood transfusion or any blood products
             or cytokines be used within 14 days prior to testing）:

               -  Hemoglobin ≥8.0g/dL.

               -  White blood cell count ≥ 3.0×10^9/L.

               -  Platelet count ≥ 75×10^9/L.

               -  Serum creatinine ≤ 1.5×upper limit of normal (ULN) or 24 hours calculated
                  creatinine clearance ≥ 50mL/min when serum creatinine >1.5×ULN (with
                  Cockcroft-Gault formula).

               -  Serum albumin ≥ 3.0 g/dL.

               -  Total bilirubin ≤ 1.5 x ULN.

               -  Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 2.5 x ULN.

               -  Amylase≤1.5×ULN. Lipase≤1.5×ULN.

               -  PT、APTT、INR≤1.5×ULN.

          8. Cardiac function index: ejection fraction (EF) > 50%, pulmonary arterial systolic
             pressure (PASP) ≤50 mmHg.

          9. Corrected QT interval (QTc) on electrocardiogram (ECG) evaluation: QTc≤450ms in males
             or ≤470ms in females.

         10. Males and females of childbearing potential and their partners voluntarily take
             contraceptive measures that the researchers believe are effective within 120 days from
             the signing of the informed consent to the last use of the research drug, or confirm
             that sterilization has been performed (at least one month before screening).

         11. Willingness and ability to comply with study procedures and follow-up examination.

        Exclusion Criteria:

          1. Received chemotherapy or radiotherapy within 28 days prior to the first
             administration, interferon or antitumor effect Chinese herbal medicine or Chinese
             patent medicine within 14 days prior to the first administration, or targeted BCR-ABL1
             TKI within 7 days prior to the first administration, or hydroxyurea or anagrelide
             within 24 hours after the first administration, or adverse events (except alopecia)
             caused by previous treatment and have not recovered.

          2. The patients who received any other investigating drugs within 14 days prior to first
             administration.

          3. Patients who have progressed to accelerated phase (AP) or blast phase (BP) in the
             past.

          4. Patients who are currently receiving treatment with a medication that has the
             potential to interact with research drug

          5. Have previously been treated with ponatinib or HQP1351 (or drugs of similar
             composition).

          6. Absorption disorder syndrome or other diseases affecting oral drug absorption.

          7. Have any history of heart or vascular disease, such as hypertension (systolic blood
             pressure (HBP)> 140mmHg and/or diastolic blood pressure > 90mmHg), or take medications
             that are known to cause QT prolongation. The patients with well controlled HBP can be
             considered to be included.

          8. Pulmonary systolic pressure (PSP) of echocardiography is more than 50 mmHg, or there
             is clinical symptom related to pulmonary hypertension.

          9. Have a history of serious cardiovascular diseases during the previous treatment of
             chronic myeloid leukemia with TKI, including myocardial infarction, unstable angina
             pectoris, severe arrhythmia and congestive heart failure.

         10. Underwent autologous or allogeneic stem cell transplant.

         11. CML-CP patient currently diagnosed as Complete cytogenetic remission (CCyR).

         12. Have diseases with abnormal bleeding and coagulation function, or have a bleeding
             disorder unrelated to CML within 3 months before first dose of study drug.

         13. Underwent major surgery (except minor surgical procedures, such as placement or bone
             marrow biopsy) with 14 days prior to the first dose of study drug.

         14. Require concurrent treatment with immunosuppressive agents, other than corticosteroids
             prescribed for a short course of therapy (It is defined as a daily dose of
             corticosteroids less than 30 mg prednisone or the same amount of other corticosteroids
             within 7 days).

         15. Have active nervous system (CNS) disease as evidence by cytology or pathology. In the
             absence of clinical CNS disease, lumbar puncture is not required.

         16. History of another primary malignancies.

         17. Active symptomatic infection.

         18. Known to be allergic to study drug ingredients or their analogues.

         19. Female patients with blood β-Human chorionic gonadotropin (HCG)positive, pregnant or
             lactating or expecting pregnancy during the study program.

         20. Suffer from any condition or illness that, in the opinion of the Investigator or the
             medical monitor, would compromise patient safety or interfere with the evaluation of
             the safety of the research drug.